Trial Profile
An Open-label, Dose Escalation, Pharmacodynamic, Pharmacokinetic, and Effect of Food Phase 1 Study of E7820, to Determine the Maximum Tolerated Dose Following Twice Daily Oral Administration in Subjects With Unresectable Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs E 7820 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Eisai Inc
- 05 Feb 2018 Status changed from active, no longer recruiting to completed.
- 21 Jul 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2018.
- 19 Apr 2016 Planned End Date changed from 1 Sep 2014 to 1 Dec 2016.